Prelude Therapeutics
PRLD
59 hedge funds and large institutions have $188M invested in Prelude Therapeutics in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 23 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
11% more funds holding
Funds holding: 53 → 59 (+6)
1.85% less ownership
Funds ownership: 87.35% → 85.5% (-1.8%)
11% less capital invested
Capital invested by funds: $210M → $188M (-$22.1M)
43% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$549K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$511K |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$348K |
| 4 |
Citigroup
New York
|
+$330K |
| 5 |
6CM
683 Capital Management
New York
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$3.86M |
| 2 |
Morgan Stanley
New York
|
-$563K |
| 3 |
UBS AM
Chicago,
Illinois
|
-$427K |
| 4 |
BlackRock
New York
|
-$420K |
| 5 |
Two Sigma Investments
New York
|
-$344K |
PRLD Hedge Fund Activity: Q4 2022 in Review
59 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q4 2022, worth a combined $188M — down 11% from $210M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PRLD positions and 5 closed out — a net gain of 7 holders — while 13 added to existing stakes and 23 trimmed.
The largest buyer was Barclays, adding an estimated $549K. The largest seller was HHLR Advisors, exiting entirely with an estimated $3.86M sold.
- 59 institutional investors held Prelude Therapeutics (PRLD) as of Q4 2022, up from 53 in Q3 2022.
- Funds reported $188M of Prelude Therapeutics stock for Q4 2022, down 11% quarter-over-quarter.
- 12 funds opened new Prelude Therapeutics positions in Q4 2022 and 5 closed out, a net change of +7 holders.
- The largest Prelude Therapeutics buyer in Q4 2022 was Barclays, an estimated $549K added.
- The largest Prelude Therapeutics seller in Q4 2022 was HHLR Advisors, an estimated $3.86M sold.
Based on aggregated 13F filings for Q4 2022.